Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 103, Issue 2, 2011, Pages 317-324

  Maier Hauff, Klaus ^a   Ulrich, Frank ^b   Nestler, Dirk ^a   Niehoff, Hendrik ^b   Wust, Peter ^c   Thiesen, Burghard ^d   Orawa, Helmut ^c   Budach, Volker ^c   Jordan, Andreas ^c,d  

^a Bundeswehrkrankenhaus Berlin ^*  (Germany)

^b HELIOS KLINIKUM KREFELD   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d MagForce Nanotechnologies AG   (Germany)

Author keywords

Glioblastoma; Magnetic nanoparticles; Radiotherapy; Recurrence; Thermotherapy

Indexed keywords

ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GLIOBLASTOMA; HUMAN; HYPERTHERMIC THERAPY; MAGNETOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEURONAVIGATION; OVERALL SURVIVAL; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RADIATION DOSE FRACTIONATION; RECURRENT CANCER; STEREOTACTIC TREATMENT; SURVIVAL TIME; THERAPY EFFECT; TUMOR VOLUME;

BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FERRIC COMPOUNDS; GLIOBLASTOMA; HUMANS; HYPERTHERMIA, INDUCED; KAPLAN-MEIER ESTIMATE; MAGNETICS; MIDDLE AGED; NANOPARTICLES; NEOPLASM RECURRENCE, LOCAL; NEURONAVIGATION;

EID: 79959846524     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0389-0     Document Type: Article

References (41)

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
2. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466
3. Hau P, Baumgart U, Pfeifer K et al (2003) Salvage therapy in patients with glioblastoma: is there any benefit? Cancer 98:2678-2686
4. Sawaya R (1999) Extent of resection in malignant gliomas: a critical summary. J Neurooncol 42:303-305
5. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392-401
6. Nieder C, Astner ST, Mehta MP, Grosu AL, Molls M (2008) Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol 31:300-305
7. Cho KH, Hall WA, Gerbi BJ, Higgins PD, McGuire WA, Clark HB (1999) Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys 45:1133-1141
8. Hudes RS, Corn BW, Werner-Wasik M et al (1999) A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys 43:293-298 (Pubitemid 29091467)
9. Larson DA, Suplica JM, Chang SM et al (2004) Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neuro-oncol 6:119-126 (Pubitemid 38455758)
10. Simon JM, Cornu P, Boisserie G et al (2002) Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. Int J Radiat Oncol Biol Phys 53:67-74 (Pubitemid 34467054)
11. Chan TA, Weingart JD, Parisi M et al (2005) Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys 62:1133-1139 (Pubitemid 40884428)
12. Combs SE, Gutwein S, Thilmann C, Huber P, Debus J, Schulz-Ertner D (2005) Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J Neurooncol 74:167-171 (Pubitemid 41478913)
13. Vordermark D, Kolbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M (2005) Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer 5:55
14. Shrieve DC, Alexander E 3rd, Wen PY et al (1995) Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 36:275-282 discussion 274-282
15. Gwak HS, Youn SM, Kwon AH, Lee SH, Kim JH, Rhee CH (2005) ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas: phase II study. J Neurooncol 75:173-180 (Pubitemid 41819721)
16. Brandes AA, Tosoni A, Franceschi E et al (2009) Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol 64:769-775
17. Keles GE, Lamborn KR, Chang SM, Prados MD, Berger MS (2004) Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg 100:41-46 (Pubitemid 38017813)
18. Wick A, Felsberg J, Steinbach JP et al (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357-3361 (Pubitemid 47325623)
19. Brandes AA, Tosoni A, Cavallo G et al (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95:1155-1160 (Pubitemid 44658477)
20. Buie LW, Valgus J (2008) Bevacizumab: a treatment option for recurrent glioblastoma multiforme.Ann Pharmacother 42:1486-1490
21. Rich JN, Reardon DA, Peery T et al (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133-142 (Pubitemid 41095125)
22. Schwarzmaier HJ, Eickmeyer F, von Tempelhoff W et al (2006) MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: preliminary results in 16 patients. Eur J Radiol 59:208-215 (Pubitemid 44093175)
23. Gutin PH, Iwamoto FM, Beal K et al (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75:156-163
24. Darakchiev BJ, Albright RE, Breneman JC, Warnick RE (2008) Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. J Neurosurg 108:236-242 (Pubitemid 351213285)
25. Boiardi A, Silvani A, Eoli M et al (2008) Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival? J Neurooncol 88:105-113
26. Sneed PK, Stauffer PR, McDermott MW et al (1998) Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost ± hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 40:287-295 (Pubitemid 28114370)
27. Wust P, Hildebrandt B, Sreenivasa G et al (2002) Hyperthermia in combined treatment of cancer. Lancet Oncol 3:487-497 (Pubitemid 34863670)
28. van der Zee J, Gonzalez Gonzalez D, van Rhoon GC, van Dijk JD, van Putten WL, Hart AA (2000) Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 355:1119-1125 (Pubitemid 30172932)
29. Issels RD, Lindner LH, Verweij J, Wust P (2010) Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 11:561-570
30. Jordan A, Scholz R, Maier-Hauff K et al (2006) The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncol 78:7-14 (Pubitemid 43786652)
31. Johannsen M, Thiesen B, Gneveckow U et al (2006) Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer. Prostate 66:97-104 (Pubitemid 43005953)
32. Maier-Hauff K, Rothe R, Scholz R et al (2007) Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol 81:53-60 (Pubitemid 44963989)
33. Johannsen M, Gneveckow U, Taymoorian K et al (2007) Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective phase I trial. Int J Hyperthermia 23:315-323 (Pubitemid 46860598)
34. Johannsen M, Gneveckow U, Thiesen B et al (2007) Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and three-dimensional temperature distribution. Eur Urol 52:1653-1662 (Pubitemid 350052385)
35. van Landeghem FK, Maier-Hauff K, Jordan A et al (2009) Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. Biomaterials 30:52-57
36. Gneveckow U, Jordan A, Scholz R et al (2004) Description and characterization of the novel hyperthermia- and thermoablation-system MFH 300F for clinical magnetic fluid hyperthermia. Med Phys 31:1444-1451 (Pubitemid 38808512)
37. Scott CB, Scarantino C, Urtasun R et al (1998) Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40:51-55 (Pubitemid 28027566)
38. Gorlia T, van den Bent MJ, Hegi ME et al (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9:29-38
39. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578 (Pubitemid 29368260)
40. Simon R (1986) Confidence intervals for reporting results of clinical trials. Ann Intern Med 105:429-435
41. Hadjipanayis CG, Machaidze R, Kaluzova M et al (2010) EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res 70:6303-6312